Figure 7 | Scientific Reports

Figure 7

From: Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression

Figure 7

Regression of MDA-MB-231 tumor xenografts in mice treated with FCPZnO and PAC.

(A) In vivo real-time images of IRDye 680-labeled FCPZnO compared to control (IRdye-680). (B) Drug treatment groups received PAC (10 mg/kg, i.v.), equivalent dose of PAC in nanoformulation (10 mg/kg, i.v.) and equivalent weight of nanocarrier (i.v.). Tumor volumes in the FCPZnO group were significantly diminished in comparison with free PAC at 35 days after treatment (P < 0.05). (C) Tumor volume (D) Tumor mass (E) spectral shift of tumor sections of FCPZnO-treated mice (a and b). (F) FESEM image of tumor cross section area for EDX elemental mapping of corresponding sample zinc (yellow), oxygen (green) and carbon (red) and corresponding EDX spectra.

Back to article page